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INTRODUCTION
The first sibling allogeneic bone marrow transplant in Ireland 
was undertaken in Belfast in December 1980. Up to March 
2005  a  total  of  139  transplants  were  carried  out  mainly 
in the Royal Victoria Hospital but also in the Belfast City 
Hospital. Over 25 years the transplant unit has grown in both 
volume and experience with 42 patients having undergone 
transplant since the year 2000. Although representing a small 
proportion of transplants performed throughout Europe, both 
survival, morbidity and mortality rates have been found to be 
comparable to national and international averages. This study 
highlights both the remarkable changes in transplantation over 
time and the outcome of sibling allogeneic transplant in the 
major haematological illnesses.
BACKGROUND
Bone marrow transplantation (BMT) is currently an important 
treatment option in a variety of malignant and non-malignant 
diseases1. This practice began as a means of repopulating the 
haemopoietic stem cell compartment following myeloblative 
exposure to radiation as a means of ‘rescue’. It has since 
evolved into a means to induce anti-tumour responses when 
used in malignancy2.
BMT can be either autologous (the transferred haematopoietic 
stem cells (HSC) are obtained from the patient) or allogeneic 
(HSC are from a donor that is optimally, totally matched at 
the major histocompatibility complex loci)2.
Classically,  BMT  involves  some  form  of  cytoreductive 
conditioning  of  the  recipient  with  irradiation  and/or 
chemotherapy.  HSC  were  previously  provided  exclusively 
by bone marrow cells however other sources have shown 
efficacy  including  mobilised  peripheral  blood  and  more 
recently cord blood.  Subsequent HSC engraftment requires 
immunosuppression2.
Bone marrow transplant is, however, hampered by significant 
toxicities, which limit its efficacy. Graft versus host disease 
(GVHD) is ultimately the result of donor T cell attack on the 
immunocompromised  and  genetically  dissimilar  recipient 
resulting in multi-organ damage and morbidity2. These same 
T cells also seem to have graft versus tumour (leukaemia) 
effect as demonstrated by studies in which removal of T cells 
prevented GVHD but also increased relapse rates2.
Further complications include a profound period of immune 
deficiency leaving the patient susceptible to opportunistic 
infections and donor graft rejection2.
Unfortunately  common  means  to  prevent  or  treat  GVHD 
with  systemic  immunosuppression  (e.g.  cyclosporin  / 
corticosteroids)  can  lead  to  impaired  immune  recovery, 
increased opportunistic infections and higher relapse rates2.
METHODS 
Data was collected from both EBMT MED-B forms (forms 
submitted  to  EBMT  containing  transplant  details  and 
outcome) and patient records. Allogeneic transplants carried 
out between December 1980 and March 2005 of all ages 
were  included.  Ninety-eight  percent  of  patients  received 
bone marrow grafts from human leucocyte antigen identical 
siblings. Two were haploid identical grafts and one was an 
HLA phenotypic match.  Information at time of transplant, 
including age, gender, diagnosis and date of transplant was 
recorded. Outcome following transplant was sub-divided into 
time frames – 100 days post transplant, 100 days to 5 years 
post  transplant,  5-10  years  post  transplant  and  10+  years 
post transplant. Outcome was measured by both morbidity 
and  mortality  with  specific  complications,  disease  status, 
and cause of death being recorded. Results for the four most 
commonly  transplanted  diseases  –  Acute  lymphoblastic 
leukaemia,  acute  myeloid  leukaemia,  chronic  myeloid 
leukaemia and aplastic anaemia – were further sub-divided to 
enable specific analysis in relation to disease status.   
The data collected was ultimately compared to those noted 
in European and international databases. Information was 
gathered from the Centre for International Blood and Marrow 
Transplant Research (CIBMTR), the world’s largest clinical 
database of related blood and marrow transplants, along with 
the European group for Blood and Marrow Transplantation 
(EBMT). Results obtained including demographics, survival, 
morbidity and mortality were subsequently compared to those 
in our centre to highlight similarities in outcome.© The Ulster Medical Society, 2008.
186 The Ulster Medical Journal
www.ums.ac.uk
RESULTS
Demographics
Of the 139 patients transplanted within this time frame 86 
were male and 53 were female. The mean age was 29.8 years 
(overall range 5 – 58). The number of transplants carried 
out biennially over this time period has shown a significant 
increase from just 3 between 1980 and 1981 to 22 between 
2000 and 2001 (fig 1). The most common underlying diagnosis 
in our unit was acute lymphoblastic leukaemia (ALL) with 
forty-five cases (33%) transplanted within this time period. 
Thirty-six patients (26%) had a diagnosis of acute myeloid 
leukaemia  (AML),  twenty-five  (18%)  of  chronic  myeloid 
leukaemia  (CML),  fourteen  (10%)  of  aplastic  anaemia, 
six  (4%)  of  multiple  myeloma  and  two  (1%)  of  chronic 
lymphocytic leukaemia.  The remaining eleven patients were 
classified as other diagnoses (Fig 2).
Overall Survival
Overall  survival  following  transplant,  calculated  as  those 
alive at time of analysis, was found to be 44.6% (62 patients). 
Seventy-seven  patients  (55.4%)  were  deceased.  Overall 
median survival was 60 months. Ten-year transplant survival 
is shown in fig. 3. Of those that died, 42 were recorded to be 
secondary to treatment related mortality and 35 secondary 
to  relapse. When  subdividing  treatment  related  mortality, 
graft  versus  host  disease  (GvHD)  was  found  to  be  the 
most common underlying cause with 23% of deaths being 
secondary to either acute or chronic GvHD.
Graft versus Host Disease
Forty-seven  patients  in  total  developed  acute  GvHD 
(developing <100 days after transplant) while 32 patients 
developed chronic GVHD (>100 days). Acute GvHD was 
graded using the Glucksberg staging depending on the extent 
of skin, liver and gut involvement. Twenty-five patients were 
assessed as grade I (mild) or grade II (moderate), 22 were 
grade III (severe) or grade IV (life threatening). Of those 
with grade III or IV aGvHD only one patient is alive today. 
The majority of patients died as a subsequence of GVHD 
(90%). In contrast, almost half the patients with grade I or II 
aGVHD are alive today. Only one death, within this group, 
was recorded as secondary to GVHD.
This finding highlights the extensive mortality associated with 
GVHD particularly in grade III and IV disease.
Disease Specific Survival
Acute Leukaemia
Of those patients with ALL (45 pts), 38% were alive at time 
of analysis. Disease relapse accounted for the majority (64%) 
of deaths with 36% as a result of treatment related mortality 
(e.g. graft versus host disease, infection). Alternatively 50% 
of patients with AML were alive at the time of analysis with 
equal  mortality  rates  from  relapse  and  treatment  related 
causes.
These results do appear to demonstrate an improved outcome 
after transplant in the AML group; however, it is important 
to note that the majority of deaths in the ALL group were 
secondary to disease relapse.
Chronic Myeloid Leukaemia
Those patients with a diagnosis of CML represented 18% of 
total transplants. Approximately half were alive at time of 
analysis (48%) with the majority of deaths being secondary 
to  treatment  related  causes  (92%).  Interestingly  a  large 
number of patients developed both acute and chronic GVHD 
(44% and 37% respectively). It is well known that donor 
cells have the capacity to control residual leukaemic cells, a 
phenomenon known as the graft versus leukaemia reaction3. 
The lower incidence of relapse in this group along with a high 
incidence of GVHD highlights this effect.
Aplastic Anaemia
Fourteen patients with aplastic anaemia underwent transplant 
during this time period. Eight patients (57%) were alive at 
time of analysis with the longest survivor being 23 years from 
transplant. All deaths were treatment related and largely due 
to GVHD and infection. 
DISCUSSION
Since  the  1970s  bone  marrow  transplantation  has  been 
used with increasing frequency in the management of both 
malignant  and  non-malignant  diseases1.  Interest  in  the 
effects of radiation on the body post-world war II, led to 
studies into the damaging effects on the bone marrow, with 
laboratory observations and animal studies forming the basis 
of transplant biology1. 
In 1956 first reports of attempts to treat humans with total 
body irradiation and marrow infusion were published1. Dr 
E  Thomas,  a  haematologist  based  in  Cooperstown,  New 
York achieved a transient graft on a leukaemic patient in 
19574. In 1959 the same group reported 2 cases of isologous 
transplantation for the treatment of acute leukaemia on 2 
children using marrow from their identical twin. Successful 
transplant was achieved with remissions of seven and twelve 
weeks5. Thomas later went on to receive the Nobel Prize 
for discoveries concerning organ and cell transplantation in 
19904.
A French group achieved the first persistent transplant in 
a patient with acute lymphoblastic leukaemia, reported in 
1965. The patient died 20 months after transplant from herpes 
zoster virus. Post mortem revealed no evidence of disease 
relapse3.  Over  subsequent  years  increasing  knowledge  of 
histocompatibility antigen systems led to the first successful 
allogeneic transplant using a sibling donor in 19686.   
Since this time the use of bone marrow transplantation has 
increased  substantially. Transplants  for  leukaemia  in  first 
remission  or  first  relapse  demonstrated  a  much-improved 
overall survival and subsequently this treatment was applied 
to a number of malignant and non-malignant diseases1.
Surveys  from  the  Centre  for  International  Blood  and 
Marrow Transplantation (CIBMTR) report a 630% increase 
in allogeneic transplants between 1981 and 19907. Similar 
results were also noted from the European group for Blood 
and Marrow Transplantation (EBMT) data bank revealing 
an increase from 200 transplants in 1980 to 6065 in 19928. 
Although  this  increase  can  be  partly  explained  by  better 
reporting and more complete data, this growth reflects the © The Ulster Medical Society, 2008.
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increase in units carrying out transplant.
The first allogeneic bone marrow transplant 
in Belfast took place in December 1980. 
The patient, a 12-year-old girl with ALL 
in her third complete remission, engrafted 
and survived beyond 100 days, however 
developed  complications  of  both  acute 
GVHD  and  pneumococcal  septicaemia. 
This first transplant, nevertheless, led to 
the development of the successful BMT 
unit at the Royal Victoria Hospital, which 
transferred  to  the  Belfast  City  Hospital 
in  2001.  Since  1980,  the  frequency  of 
transplantation in Belfast has also increased 
substantially with a 630% increase from 
1980 to 2001 (Fig.1).
Further distinct changes over time have been 
noted in keeping with worldwide records. 
CIBMTR highlighted the increasing age 
of  patients  undergoing  transplant  with 
more  patients  over  the  age  of  50  being 
transplanted  as  the  procedure  improved 
and  progressed9. Again  our  unit  showed 
similar results with an increase in patients 
over the age of 41 being transplanted from 
1990, and the first patient over 50 to be 
transplanted in 2002 (Figs 4 and 5).
Between 1980 and 2005, the most common 
underlying  disease  requiring  transplant 
in Belfast was found to be ALL (33%). 
This was followed by AML with 26% of 
the  total  patients  transplanted  suffering 
from this disease. The CIBMTR report a 
larger frequency of transplants for AML 
with  nearly  double  the  frequency  of 
ALL transplants9. This is again noted in 
the British Society of Blood & Marrow 
Transplantation  (BSBMT)  register  with 
~  30%  of  allo-transplants  carried  out 
for AML and 19% for ALL each year10. 
The reason for this is unclear though our 
sample size is small for comparison.  Also 
prior to the year 2000 a larger proportion 
of patients with ALL were transplanted as 
at this time the numbers were inclusive of 
children.
Survival
The disease state at transplant has been 
shown  to  be  of  primary  importance  in 
assessing  risk  of  relapse  and  long  term 
survival  following  transplant7.  Data 
from  the  CIBMTR  shows  a  significant 
(P=0.0001)  difference  between  the 
probability of survival following transplant 
in those in CR1 (1st complete remission) 
and those in CR29.
Acute Myeloid Leukaemia
In the literature, the long-term survival in 
Fig 1. Number of Allogeneic transplants carried out over time
Fig 2. Primary diagnosis of those undergoing transplant in Belfast
Fig 3. Overall probability of survival following transplant in Belfast© The Ulster Medical Society, 2008.
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AML with chemotherapy alone has been 
shown to be ~40%7.  In our group, overall 
survival of those patients with AML who 
underwent allogeneic transplant was noted 
to  be  47%.  Further  evaluation  revealed 
the survival was indeed related to disease 
status at transplant and these statistics were 
comparable with international figures (fig. 
6). Those transplanted in CR1 were noted 
to have improved survival with an actuarial 
5-year survival of 59% in CR1 compared 
to 33% in CR2. The CIBMTR record a 
3-year survival in those patients in CR1 
of 61%, while those in CR2 were noted 
to have a survival at three years of 48%9. 
Although  three-year  survival  statistics 
were not available in our study group, due 
to timing of assessment forms, the results 
in our unit are comparable.
Acute Lymphoblastic Leukaemia
Similar differences are noted in those with 
Acute  Lymphoblastic  leukaemia  (ALL). 
Childhood ALL has been shown to have a 
long-term survival of well over 75% using 
chemotherapy alone, however in the adult 
population this can be as low as 35%11. 
For this reason allogeneic transplant is an 
important treatment option for adults with 
this disease. Overall survival for this group 
was found to be 33%. However, actuarial 
5-year  survival  of  those  transplanted  in 
CR1 was greater at 47% compared to 31% 
in CR2. These results are comparable with 
the CIBMTR who report 3 year survival of 
those in CR1 of 48% with the survival in 
CR2 6-10% lower (Fig 7).
Chronic Myeloid Leukaemia and 
Aplastic Anaemia
Due to small numbers within these sub-
groups,  comparisons  with  international 
data  were  felt  to  be  unreliable  and 
therefore not performed. 
Overall Survival
Overall mortality following transplantation 
in our group of patients was 55.4% with 
median  survival  at  60  months  (fig.  4). 
In  order  to  develop  and  improve  the 
transplant  procedure,  it  is  important  to 
determine the underlying cause of death 
in this group. The most common cause of 
death during the overall time period was 
disease relapse with a total of 33 patients 
(45%) dying from progressive disease (Fig. 
8). The remaining deaths were recorded 
as treatment related and subdivided into 
GVHD, infection, interstitial pneumonitis, 
organ toxicity and other. As can be seen 
from Fig. 10 the second most common 
Figs 4 and 5. Trends in recipient age noted over time (1984-2002). Belfast (top) 
compared to CIBM TR8
Fig 6. Survival plot of patients with AML transplanted in both CR1 and CR2© The Ulster Medical Society, 2008.
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cause  of  death  was  noted  to  be  GVHD 
(22%)  followed  by  infection  (16%). 
CIBMTR have demonstrated similar results 
with  death  secondary  to  relapse  at  34%, 
infection 17% and GVHD 15%9.  
Since the introduction of transplant, relapse 
and  non-relapse  mortality  have  made  a 
significant impact on overall survival rates12. 
The majority of deaths have been found to 
be related to toxicity from the conditioning 
regime,  infections,  GvHD  and  disease 
relapse12. This has led to major progress in 
supportive  care,  immunosuppression  and 
infection management during the transplant 
period12.  During  the  pancytopenic  phase 
many units (including Belfast) nurse patients 
in  single  rooms  using  clean  air  systems.   
The  use  of  prophylactic  anti-fungals 
and  anti-virals  is  also  well  recognised7. 
Advances  in  diagnostic  techniques  have 
led  to  improved  recognition  of  infective 
organisms,  with  superior  broad-spectrum 
antibiotics enhancing survival12.
As a result of the improving management 
of these patients, death from infection has 
reduced  significantly  over  time12  (fig.  9). 
Mortality from infection can be seen to be 
decreasing over time, however, the ongoing 
risk  of  death  from  GVHD  and  disease 
relapse remains a significant challenge to 
haematologists (fig. 9). 
CONCLUSIONS
The data collected from patients in our unit 
highlights the success of transplantation in 
Belfast.  In terms of morbidity, mortality 
and survival, results are comparable to those 
in international and European records.
Over the past 20 years advances have been 
made in both the transplant procedure and 
post transplant care leading to improvements 
in survival which are set to continue. With 
the new era of reduced intensity allografts 
the opportunities for those older patients 
previously  unsuitable  for  transplant  are 
encouraging.  
As  a  successful  transplant  unit,  we 
look  forward  to  continued  advances  in 
the  management  of  patients  with  life 
threatening haematological conditions and 
ever improving survival rates.
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